Compass Pathways Between Phase Three Success and a Commercial Timeline Nobody Quite Believes Yet

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

CMPS typically reports earnings before market open, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

Historical price action around CMPS earnings reveals significant volatility with an average absolute Day 0 move of 10.06%. The most recent report on May 13, 2026, produced the strongest reaction in the dataset, with the stock surging 16.97% on Day 0 following the substantial earnings beat, though it gave back 3.10% the following session. This pattern of strong initial reactions followed by partial reversals appears common—the November 2025 report saw an 11.43% Day 0 gain that reversed into a 17.19% decline on Day +1.

The data shows directional unpredictability, with Day 0 moves ranging from a 23.10% decline (October 2024) to the 16.97% surge in May 2026. Notably, the magnitude of the Day 0 move doesn't always correlate with earnings surprise direction—the March 2026 report produced only a 2.25% decline despite a significant miss. The average Day +1 move of 3.97% suggests continued volatility into the second session, though with less magnitude than the initial reaction. The wide average Day 0 range of 13.43% indicates substantial intraday volatility regardless of the closing direction, creating both risk and opportunity for traders positioning around the event.

Part 2.2: Options Market Expected Move

The options market is pricing a 14.62% expected move for the August 21 expiration, which is notably higher than the 10.06% average historical Day 0 move but below the 13.43% average Day 0 range. This suggests options traders are anticipating above-average volatility for this particular release, possibly reflecting heightened uncertainty around regulatory timeline updates and clinical data disclosures that could materially impact the company's valuation.

Part 3: What Analysts Are Saying

Analysts maintain strong conviction on Compass Pathways, with the consensus rating at 4.72 out of 5.00—firmly in Strong Buy territory. The analyst community shows overwhelming bullish sentiment: 15 of 18 analysts rate CMPS a Strong Buy, with just 1 Moderate Buy and 2 Hold ratings. Notably, there are zero sell ratings of any kind, reflecting broad confidence in the company's regulatory and commercial prospects.

The mean price target of $23.20 implies substantial 97% upside from the current price of $11.80, though the wide range of targets—from a low of $13.00 to a high of $70.00—underscores significant disagreement about the ultimate value depending on execution and timeline assumptions. The high-end target suggests some analysts see potential for nearly 500% upside if CMPS successfully navigates FDA approval and captures meaningful market share in the TRD indication.

Sentiment has improved over the past month, with the number of Strong Buy ratings increasing from 14 to 15. The average recommendation ticked up slightly from 4.71 to 4.72, indicating analysts are becoming marginally more bullish even as the stock has pulled back from recent highs. This strengthening conviction likely reflects growing confidence in the regulatory pathway following the Q1 earnings beat and positive updates on the company's progress toward NDA submission and commercial readiness.

Part 4: Technical Picture

The Barchart Technical Opinion currently shows a Buy signal at 40%, representing a significant deterioration from 56% Buy last week and 100% Buy last month. This weakening technical picture reflects recent price pressure as CMPS has pulled back from higher levels, though the signal remains in buy territory.

Timeframe Analysis:

• Short-term (Hold): Neutral reading indicates near-term momentum has stalled, suggesting consolidation or indecision in the immediate trading environment
• Medium-term (50% Buy): Moderate buy signal reflects mixed intermediate-term momentum as the stock works through recent volatility
• Long-term (100% Buy): Strong buy signal demonstrates solid longer-term uptrend remains intact despite near-term weakness

Trend Characteristics: The overall trend is characterized as Good strength but Weakening direction, suggesting the underlying uptrend structure remains sound but momentum has faded heading into the earnings event, creating a more cautious setup than existed earlier in the quarter.

At $11.80, CMPS is trading above its 5-day ($11.37), 10-day ($11.39), 100-day ($10.06), and 200-day ($8.28) moving averages, but has slipped below both its 20-day ($12.18) and 50-day ($12.47) moving averages. This configuration suggests the stock is in a short-term pullback within a longer-term uptrend—a technically neutral setup heading into earnings. The fact that CMPS remains well above its 200-day moving average provides a supportive longer-term foundation, but the breach of the 20-day and 50-day averages indicates recent momentum has turned negative. Given the 14.62% expected move and historical volatility around earnings, the current technical setup is neither strongly supportive nor cautionary—instead, it reflects a stock in consolidation mode where the earnings catalyst will likely determine the next directional move. Traders should note that a strong beat could quickly reclaim the 20-day and 50-day averages and resume the uptrend, while a disappointment could test support at the 100-day moving average near $10.